TP53 and acute myeloid leukemia: Notably, TP53 mutations, with an overall incidence of about 10% in de novo MDS and 40% in therapy-related MDS (t-MDS patients) [12,13], is independently associated with resistance to conventional therapies, rapid transformation to AML, and a poor outcome [14].